Highest-materiality recent filing
Bolt Biotherapeutics reports FY2025 loss from ops $36.1M; cash $31.8M into 2027
Collaboration revenue $7.7M for FY2025, flat YoY; Q4 2025 revenue $2.5M vs $0 in Q4 2024.
Bolt Biotherapeutics Q3 2025: operating loss $7.7M, cash $38.8M; BDC-4182 data expected 3Q26
Collaboration revenue $2.2M (vs $1.1M Q3 2024); R&D expenses $6.5M (down 53% YoY).
Bolt Biotherapeutics cuts workforce 50% and delays BDC-4182 data to Q3 2026
Workforce reduced by ~50% (approx. 20 employees); pre-tax charges $1.5-2.0M in Q4 2025.
Bolt Biotherapeutics Q2 2025 loss from ops $9.2M; cash $48.5M; BDC-4182 Phase 1 ongoing
Collaboration revenue $1.8M (Q2 2024: $1.3M); R&D expenses down to $7.5M from $15.4M.
Bolt Biotherapeutics stockholders approve reverse stock split amendment at 2025 annual meeting
Reverse stock split amendment approved: 20,983,236 votes for, 3,224,611 against (86.9% of votes cast).
Bolt Biotherapeutics Q1 2025: operating loss $12.1M; cash $58M; BDC-4182 Phase 1 open
Collaboration revenue $1.2M (down from $5.3M in Q1 2024) due to completion of Innovent agreement.
Bolt Biotherapeutics Q4 2024 loss from ops $16.9M; cash $70.2M; BDC-4182 starts trial Q2 2025
Q4 2024 loss from operations $16.9M vs $19.8M in Q4 2023; full-year loss $73.0M vs $76.2M.
Transfer approved Jan 2, 2025; effective at market open Jan 6, 2025.
Bolt Biotherapeutics Q3 2024: cash $84.4M; BDC-3042 advances to 10 mg/kg cohort
Cash $84.4M as of Sept 30, 2024; expected to fund operations through mid-2026.
Bolt Biotherapeutics Q2 2024 loss from operations $22.6M; cash $97.5M, BDC-3042 advances to Cohort 6
Loss from operations of $22.6M for Q2 2024 vs $19.8M in Q2 2023; restructuring charges of $3.6M.
Bolt Biotherapeutics receives Nasdaq bid price deficiency notice; 180 days to comply
Avg closing price of common stock fell below $1.00 over prior 30 trading days as of July 1, 2024.
Bolt Biotherapeutics restructures, cuts 50% workforce, CEO replaced; Q1 loss $17.1M
Q1 2024: loss from ops $17.1M; collaboration revenue $5.3M; cash $112.8M.
Bolt Biotherapeutics reports Q4/FY2023 results; cash $128.6M funds through late 2025
Cash, cash equivalents, and marketable securities at $128.6M as of Dec 31, 2023; expected to fund through late 2025.
Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed
Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.
Bolt Biotherapeutics Q1 2023 net loss $18.4M; cash $171M; BDC-1001 Phase 2 plans
Net loss from operations $18.4M vs $23.9M in Q1 2022; collaboration revenue $1.8M (up from $0.8M).
Bolt Biotherapeutics reports positive BDC-1001 Phase 1 data; advances to Phase 2; cash $192.8M
BDC-1001 elicited objective responses including partial responses and stable disease across multiple HER2+ solid tumors as monotherapy and with nivolumab.
Bolt Biotherapeutics Q3 2022 operating loss $22.3M; cash $209.6M funds through 2025
Cash $209.6M as of Sep 30, 2022; expected to fund operations and milestones through 2025.
Bolt Biotherapeutics Q2 loss $23.1M; cash $223.6M extends runway to 2025
Collaboration revenue $1.4M vs $0 in Q2 2021; R&D spend $18.9M, G&A $5.5M.
Bolt Biotherapeutics reports 2021 results; cash $271.6M, BDC-1001 on track for RP2D in 2022
Cash, cash equivalents, and marketable securities $271.6M at Dec 31, 2021 vs $22.8M at end 2020; runway into 2024.
Bolt Biotherapeutics CSO David Dornan resigns, stays as consultant for 6 months
David Dornan, Ph.D. resigned as Chief Scientific Officer effective March 11, 2022.
Amended supply agreement with EirGenix for bulk drug substance EG12014, a trastuzumab biosimilar used in BDC-1001 HER2 Boltbody ISAC.
Bolt Biotherapeutics reports interim Phase 1/2 BDC-1001 data: safe, 1 durable PR at 52 weeks, no CRS
BDC-1001 showed favorable safety in 57 patients; no dose-limiting toxicities up to 20 mg/kg Q3W and 12 mg/kg Q2W.
Bolt Biotherapeutics Q3 2021: cash $290.5M; BDC-1001 interim data at ESMO I-O in Dec
Cash, cash equivalents and marketable securities $290.5M at Sep 30, 2021; plus $5M upfront from Innovent in Oct.
Bolt Biotherapeutics Q2 cash $310.9M; R&D spend doubles; Genmab collaboration on track
Cash, cash equivalents, and marketable securities of $310.9M as of June 30, 2021, expected to fund operations through end of 2023.
Effective September 3, 2024, the Board appointed Jakob Dupont, M.D., Ph.D., to serve as a Class II member of the Board.
On September 1, 2024, Frank D. Lee notified the Company of his resignation as a member of the Board and the committees thereof, effective as of September 3, 2024.
On August 28, 2024, James Healy, M.D., Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of September 3, 2024.
On May 13, 2024, Edgar G. Engleman, M.D. notified the Company of his resignation as a member of the Company's Board of Directors (the “Board”) and from all committees of the Board on which he served, effective as of May 15, 2024.
Edith A. Perez, M.D. is stepping down as the Company’s Chief Medical Officer of the Company, effective as of May 15, 2024.
Randall C. Schatzman, Ph.D. is stepping down as the Company’s Chief Executive Officer and has resigned as a member of the Board, both effective as of May 15, 2024.
Randall C. Schatzman, Ph.D. is stepping down as the Company’s Chief Executive Officer and has resigned as a member of the Board, both effective as of May 15, 2024.
the Board then appointed Laura Berner to the Board as a Class I director of the Company, effective immediately
On March 1, 2022, David Dornan, Ph.D. notified Bolt Biotherapeutics, Inc. of his resignation as our Chief Scientific Officer, effective March 11, 2022.
On December 14, 2021, upon recommendation of the Nominating and Corporate Governance Committee, the Board appointed Nicole Onetto to the Board as a Class III director of the Company, effective immediately, to fill the vacancy on the Board.
On December 13, 2021, Ashish Khanna, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
On November 15, 2021, Peter Moldt, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event earnings